Informed Consent
Written informed consent was obtained from all individual participants included in the study.

Author contributions

F.S. and B.S. designed the research; F.S. analysed the data and B.S. checked the analysis code; F.S. drafted the manuscript and B.S. revised it; T.N.M.N., and H.B. contributed important intellectual content to the discussion. All authors were involved in the interpretation and discussion of results.

Data Availability Statement

The data that support the findings of this study are available from the UK Biobank. Restrictions apply to the availability of these data, which were used under license for this study. Data and analysis code (SAS) are available [https://www.ukbiobank.ac.uk/] with the permission of UK Biobank after approval of a research proposal and payment of a fee.

ORCID

Fatemeh Safizadeh - None
Thi Ngoc Mai Nguyen - None
Hermann Brenner - None
Ben Schöttker - 0000-0002-1217-4521

References

1. Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221-224.
2. Kreutz R, Algharably EAE, Azizi M, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020;116(10):1688-1699.
3. Del Turco S, Vianello A, Ragusa R, Caselli C, Basta G. COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge? Thromb Res. 2020;196:143-151.
4. Mascolo A, Scavone C, Rafaniello C, et al. The Role of Renin-Angiotensin-Aldosterone System in the Heart and Lung: Focus on COVID-19. Front Pharmacol. 2021;12:667254.
5. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet.2020;395(10223):497-506.
6. Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.J Travel Med. 2020;27(3).
7. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation.2005;111(20):2605-2610.
8. Speth RC. Keep taking your ACE inhibitors and ARBs during the COVID 19 pandemic. J Travel Med. 2020;27(3).
9. Tomasoni D, Italia L, Adamo M, et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail.2020;22(6):957-966.
10. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.N Engl J Med. 2020;382(25):2441-2448.
11. Ferrari F, Martins VM, Fuchs FD, Stein R. Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review.Clinics (Sao Paulo). 2021;76:e2342.
12. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.N Engl J Med. 2020;382(25):2431-2440.
13. Simko F, Hrenak J, Adamcova M, Paulis L. Renin-Angiotensin-Aldosterone System: Friend or Foe-The Matter of Balance. Insight on History, Therapeutic Implications and COVID-19 Interactions. Int J Mol Sci. 2021;22(6).
14. Alves M, Fernandes MA, Bahat G, et al. Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications. Eur Geriatr Med. 2021.
15. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779.
16. UK Biobank. Facilitating COVID-19 research. https://www.ukbiobank.ac.uk/enable-your-research/about-our-data/covid-19-data. Published 2021. Updated 11/12/2020. Accessed 07/07/2021, 2021.
17. Khanji MY, Aung N, Chahal CAA, Petersen SE. COVID-19 and the UK Biobank-Opportunities and Challenges for Research and Collaboration With Other Large Population Studies. Front Cardiovasc Med. 2020;7:156.
18. Public Health England. Coronavirus (COVID-19) in the UK https://coronavirus.data.gov.uk/details/vaccinations. Published 2021. Updated 07/07/2021. Accessed 07/07/2021, 2021.
19. Townsend P. Deprivation. Journal of Social Policy.1987;16(2):125-146.
20. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
21. Hippisley-Cox J, Young D, Coupland C, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart.2020;106(19):1503-1511.
22. Savarese G, Benson L, Sundstrom J, Lund LH. Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis. Eur J Heart Fail. 2021;23(3):476-485.
23. Kaur U, Chakrabarti SS, Patel TK. Renin-angiotensin-aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis. Ther Adv Drug Saf. 2021;12:20420986211011345.
24. Ren L, Yu S, Xu W, Overton JL, Chiamvimonvat N, Thai PN. Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis. J Cardiol. 2021;77(5):482-491.
25. Caldeira D, Alves M, Gouveia EMR, et al. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2020;31:100627.
26. Gault N, Esposito-Farese M, Revest M, et al. Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review. Fundam Clin Pharmacol. 2021.
27. Pirola CJ, Sookoian S. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis. J Infect. 2020;81(2):276-281.
28. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020;382(17):1653-1659.
29. Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Hypertension.2020;75(6):1382-1385.
30. Lopes RD, Macedo AVS, de Barros ESPGM, et al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.JAMA. 2021;325(3):254-264.
31. Puskarich MA, Cummins NW, Ingraham NE, et al. A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. EClinicalMedicine. 2021;37:100957.
Table 1. Characteristics of the study population of patients with hypertension, overall Covid-19, and hospitalized Covid-19 patient subpopulations